Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous fixed-dose pertuzumab + trastuzumab versus intravenous pertuzumab + trastuzumab in HER2-positive early breast cancer
jRCT2080224052Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: GMR of pertuzumab serum concentration (SC vs IV), GMR of trastuzumab serum concentration (SC vs IV) and 1 more. Started Sep 2018; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224052.